Not intended for UK and US audiences JASCAYD® (nerandomilast) now approved by Japan’s MHLW for the treatment of adults with idiopathic pulmonary ...

If you have scarring in your lungs, you may have been diagnosed with pulmonary fibrosis. When the reason for this scarring is unknown, your condition is called idiopathic pulmonary fibrosis (IPF). You ...

Novel targets aim to stop lung scarring—where current drugs only slow it—while improving tolerability and unlocking fibrosis ...

Toby Maher, MD, PhD, professor of clinical medicine, Keck Medicine of USC, discusses recent advancements in clinical trials for patients with idiopathic pulmonary fibrosis (IPF) and progressive ...

Dr Nathan discusses the trajectory of IPF management. How do you envision these investigational agents potentially being implemented into future treatment paradigms for idiopathic pulmonary fibrosis ...

If you’ve been coughing for weeks, blaming it on “lingering winter sniffles” or chalking it up to “just getting older,” it might be time to step away from the cough syrup and lean in for some ...

Please provide your email address to receive an email when new articles are posted on . Rentosertib was shown to be safe in a 12-week phase 2a trial in China. Two doses improved FVC vs. placebo.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The double-blind, randomized, placebo-controlled phase 3 ...

When breathing becomes increasingly difficult with no clear explanation, idiopathic pulmonary fibrosis (IPF) might be the culprit behind the concerning symptoms. This rare yet devastating lung disease ...